Cepheid sees FY13 non-GAAP EPS 41c-46c, consensus 12c Sees FY13 revenue $375M-$385M, consensus $396.52M. Sees FY13net income to range from a net loss of (5c)-1c. Expected non-GAAP net income excludes approximately $29M related to stock compensation expense and approximately $4M related to the amortization of acquired intangibles. The fully diluted share count for the year is expected to be approximately 72M, except in the event of a GAAP loss where the share count would be approximately 67M shares.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: AcelRx (ACRX) initiated with a Buy at H.C. Wainwright... Adobe (ADBE) initiated with a Perform at Oppenheimer... Antero Midstream (AM) initiated with a Buy at Ladenburg... Arbutus Biopharma (ABUS) initiated with an Outperform at JMP Securities... CSI Compressco (CCLP) initiated with a Market Perform at Wells Fargo... Cepheid (CPHD) initiated with an Equal Weight at Barclays... Cincinnati Financial (CINF) initiated with a Buy at MKM Partners... Disney (DIS) initiated with an Outperform at CLSA... Genomic Health (GHDX) initiated with an Underweight at Barclays... Green Brick (GRBK) initiated with a Neutral at Citi... Heron Therapeutics (HRTX) initiated with a Buy at BofA/Merrill... Karyopharm (KPTI) initiated with an Overweight at JPMorgan... PayPal (PYPL) initiated with a Buy at Argus... Quidel (QDEL) initiated with an Overweight at Barclays... Recro Pharma (REPH) initiated with a Buy at H.C. Wainwright.